search
Back to results

Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial (INTERACT)

Primary Purpose

Cystic Fibrosis

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Fitbit
Sponsored by
Boston Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cystic Fibrosis focused on measuring Cystic Fibrosis, Exercise, Fitbit

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A diagnosis of Cystic Fibrosis
  2. Age 18 and over
  3. Must be able to complete at least level 1 of the baseline exercise fitness test
  4. Must not have required IV antibiotics for a CF exacerbation within 30 days of starting the program

Exclusion Criteria:

  1. Pregnancy at enrollment
  2. A history of CF exacerbation requiring IV antibiotics within last month
  3. Use of a fitness tracker or similar product within 6 months of enrollment

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Fitbit

    Usual Care

    Arm Description

    Participants receive a Fitbit and are followed over the course of one year, completing surveys and exercise tests.

    Participants receive usual care over the course of one year and are offered a Fitbit in the second year. Followed to assess use of Fitbit and health outcomes.

    Outcomes

    Primary Outcome Measures

    Graded exercise test (Submaximal GXT)
    Change is submaximal GXT will be assessed for all participants

    Secondary Outcome Measures

    Fitbit activity data
    HAES (Habitual Activity Estimation Scale)
    Relative change from baseline in ppFEV1
    Forced Expiratory Volume in one second (FEV1) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
    Relative change from baseline in ppFVC
    Forced Vital Capacity in one second (FVC) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
    Relative change from baseline in ppFEF25-75
    Forced Expiratory Flow in one second (FEF25-75) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
    Incidence of exacerbations requiring IV antibiotics
    BMI
    CFQ-R (Survey on Quality of Life in Cystic Fibrosis)
    Overall qualitative assessment of participant satisfaction with the Fitbit
    Qualitative data obtained by open-ended interview
    Overall qualitative assessment of participant's potential barriers to Fitbit use
    Qualitative data obtained by open-ended interview
    Overall qualitative assessment of the participant's use of the social media associated with the device
    Qualitative data obtained by open-ended interview
    PHQ9
    Depression scale scored 0-27, with a score of 0-4 indicating minimal risk for depression/anxiety, a score of 5-9 indicating mild risk for depression/anxiety, a score of 10-14 indicating moderate risk for depression/anxiety, and a score if 15-27 indicating severe risk for depression/anxiety.
    GAD-7
    Depression scale scored 0-21, with a score of 0-4 indicating minimal risk for depression/anxiety, a score of 5-9 indicating mild risk for depression/anxiety, a score of 10-14 indicating moderate risk for depression/anxiety, and a score if 15-21 indicating severe risk for depression/anxiety.

    Full Information

    First Posted
    February 21, 2016
    Last Updated
    June 7, 2021
    Sponsor
    Boston Children's Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02700243
    Brief Title
    Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial
    Acronym
    INTERACT
    Official Title
    Pilot RCT Study Using a Fitbit Device to Improve Exercise Tolerance in 80 Patients With Cystic Fibrosis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2021
    Overall Recruitment Status
    Completed
    Study Start Date
    March 14, 2016 (Actual)
    Primary Completion Date
    April 2019 (Actual)
    Study Completion Date
    April 2019 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Boston Children's Hospital

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    In this research study the investigators want to learn more about whether using a fitness tracker and accelerometer helps patients with cystic fibrosis exercise more regularly, and in turn whether it increases exercise tolerance over the period of one year.
    Detailed Description
    The aim of this study is to evaluate whether the use of a Fitbit device and an exercise prescription is associated with increased daily activity and in turn increased exercise tolerance in young adult patients with cystic fibrosis (CF). The investigators hypothesize that use of the Fitbit and an exercise prescription will be associated with increased exercise tolerance compared to standard counseling and an exercise prescription alone. For patients with CF, young adulthood and adolescence is a significant time of vulnerability. In addition to normal behavioral challenges of adolescence and young adulthood (seeking independence/autonomy while also choosing rebellion), those with CF are often dealing with significant disease progression. Therefore, working in new innovative ways to improve adherence to regimens that improve lung function such as exercise are needed to continue to support patients during this vulnerable time. Studies of patients with cystic fibrosis have shown that regular exercise training can decrease rate of lung function decline, potentially improve lung function, and improve aerobic capacity. However, many patients do not include regular exercise in their daily routine. Successful strategies to improve adherence include providing patient specific guidelines for an appropriate exercise program, supporting participation and providing positive feedback. Overall, exercise is a crucial diagnostic and therapeutic modality for patients with Cystic Fibrosis, although awareness somewhat limited. The adult CF program at Boston Children's and Brigham & Women's Hospital established an inpatient and outpatient exercise program as part of a quality improvement effort. Patients are prescribed an individualized exercise program or exercise prescription based on their assessment during a sub-maximal effort. This program has been successful but given the rigors of daily life (e.g. school, work, family obligations), adherence is a concern with resources limiting more rigorous feedback to maintain this essential life activity.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cystic Fibrosis
    Keywords
    Cystic Fibrosis, Exercise, Fitbit

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    40 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Fitbit
    Arm Type
    Experimental
    Arm Description
    Participants receive a Fitbit and are followed over the course of one year, completing surveys and exercise tests.
    Arm Title
    Usual Care
    Arm Type
    No Intervention
    Arm Description
    Participants receive usual care over the course of one year and are offered a Fitbit in the second year. Followed to assess use of Fitbit and health outcomes.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Fitbit
    Intervention Description
    Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
    Primary Outcome Measure Information:
    Title
    Graded exercise test (Submaximal GXT)
    Description
    Change is submaximal GXT will be assessed for all participants
    Time Frame
    Two years (Enrollment, 6 months, 12 months, 24 months)
    Secondary Outcome Measure Information:
    Title
    Fitbit activity data
    Time Frame
    Two years
    Title
    HAES (Habitual Activity Estimation Scale)
    Time Frame
    Two years
    Title
    Relative change from baseline in ppFEV1
    Description
    Forced Expiratory Volume in one second (FEV1) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
    Time Frame
    Two years
    Title
    Relative change from baseline in ppFVC
    Description
    Forced Vital Capacity in one second (FVC) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
    Time Frame
    Two years
    Title
    Relative change from baseline in ppFEF25-75
    Description
    Forced Expiratory Flow in one second (FEF25-75) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
    Time Frame
    Two years
    Title
    Incidence of exacerbations requiring IV antibiotics
    Time Frame
    Two years
    Title
    BMI
    Time Frame
    Two years
    Title
    CFQ-R (Survey on Quality of Life in Cystic Fibrosis)
    Time Frame
    Two years
    Title
    Overall qualitative assessment of participant satisfaction with the Fitbit
    Description
    Qualitative data obtained by open-ended interview
    Time Frame
    Two years (6 Month Time Point)
    Title
    Overall qualitative assessment of participant's potential barriers to Fitbit use
    Description
    Qualitative data obtained by open-ended interview
    Time Frame
    Two years (6 Month Time Point)
    Title
    Overall qualitative assessment of the participant's use of the social media associated with the device
    Description
    Qualitative data obtained by open-ended interview
    Time Frame
    Two years (6 Month Time Point)
    Title
    PHQ9
    Description
    Depression scale scored 0-27, with a score of 0-4 indicating minimal risk for depression/anxiety, a score of 5-9 indicating mild risk for depression/anxiety, a score of 10-14 indicating moderate risk for depression/anxiety, and a score if 15-27 indicating severe risk for depression/anxiety.
    Time Frame
    Two years (Enrollment, 6 months, 12 months, 18 months, 24 months)
    Title
    GAD-7
    Description
    Depression scale scored 0-21, with a score of 0-4 indicating minimal risk for depression/anxiety, a score of 5-9 indicating mild risk for depression/anxiety, a score of 10-14 indicating moderate risk for depression/anxiety, and a score if 15-21 indicating severe risk for depression/anxiety.
    Time Frame
    Two years (Enrollment, 6 months, 12 months, 18 months, 24 months)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: A diagnosis of Cystic Fibrosis Age 18 and over Must be able to complete at least level 1 of the baseline exercise fitness test Must not have required IV antibiotics for a CF exacerbation within 30 days of starting the program Exclusion Criteria: Pregnancy at enrollment A history of CF exacerbation requiring IV antibiotics within last month Use of a fitness tracker or similar product within 6 months of enrollment
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ahmet Uluer, DO
    Organizational Affiliation
    Boston Children's Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    Participants will receive their graded exercise test scores as part of their clinical care and will be able to see their individual data relating to Fitbit on their own device.

    Learn more about this trial

    Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial

    We'll reach out to this number within 24 hrs